anti p mlkl  (Boster Bio)

Journal: Brain and Behavior

Article Title: Study on the Function and Mechanism of Neutrophil Extracellular Traps in Regulating Necroptosis Following Traumatic Brain Injury

doi: 10.1002/brb3.71275

Figure Lengend Snippet: Effects of Cl‐amidine and DNase I on necroptosis‐related protein expression after TBI. (A) Western blot analysis of RIP1, RIP3, MLKL, P‐RIP1, P‐RIP3, and P‐MLKL protein levels in the cortex of mice from Sham, TBI+Vehicle, TBI+Cl‐amidine, and TBI+DNase I groups. GAPDH was used as the loading control ( n = 4 per group). (B–G) Quantification of relative protein levels of RIP1, RIP3, MLKL, P‐RIP1, P‐RIP3, and P‐MLKL, normalized to GAPDH. Data are shown as mean ± SD ( n = 4 per group). Statistical significance is indicated as * p < 0.05, ** p < 0.01, *** p < 0.001, compared with the indicated groups; ns: not significant.

Article Snippet: The membranes were blocked with 5% skimmed milk prepared in TBST (Tris‐buffered saline with 0.1% Tween‐20) at room temperature for 1 h. They were then incubated overnight at 4°C with the following primary antibodies: PAD4 (1:1000, 214810, Abcam), MPO (1:1000, ab208670, Abcam), Bcl‐2 (1:1000, A0208, Abclonal), Bax (1:1000, A19684, Abclonal), RIP1 (1:1000, #3493, Cell Signaling Technology), RIP3 (1:1000, #95702, Cell Signaling Technology), MLKL (1:1000, #37705, Cell Signaling Technology), P‐RIP1 (1:1000, #31122, Cell Signaling Technology), P‐RIP3 (1:1000, #91702, Cell Signaling Technology), P‐MLKL (1:1000, #37333, Cell Signaling Technology), and GAPDH (1:1000, AB‐P‐R001, GOODHERE Biotech).

Techniques: Expressing, Western Blot, Control

Journal: Cells

Article Title: Machine Learning-Driven Multi-Omics Analysis Identifies CHP2 as a Key PANoptosis-Related Dual-Function Biomarker in Colorectal Cancer

doi: 10.3390/cells15050430

Figure Lengend Snippet: Experimental validation of CHP2 as a predictive biomarker for drug sensitivity and a driver of PANoptosis. ( A – C ) IC 50 growth inhibition curves of HCT116 and SW480 cells treated with first-line chemotherapeutic agents: ( A ) 5-fluorouracil (5-FU), ( B ) Oxaliplatin, and ( C ) Irinotecan. ( D , E ) IC50 curves for targeted agents: ( D ) Ribociclib and ( E ) Lapatinib. ( F ) Western blot analysis of key PANoptosis markers, including p-MLKL (necroptosis), N-GSDMD (pyroptosis), and Cleaved-Caspase 3 (apoptosis), in Control, CHP2-OV, and CHP2-OV-siRNA-3 groups. ( G – J ) Quantitative analysis of protein expression levels normalized to β-actin. Data are presented as mean ±SD from three independent experiments. * p < 0.05, ** p < 0.01.

Article Snippet: After the protein concentration was determined with a BCA protein assay kit (Beyotime, P0010), identical amounts of proteins were subjected to SDS-PAGE and transferred onto PVDF membranes, which were subsequently incubated with primary antibodies against CHP2 (Boster, Wuhan, China, A08478-2, 1:1000), p-MLKL (MCE, HY86069, 1:1000), GSDMD (N-terminal) (MCE, HY- P85810 , 1:1000), Cleaved Caspase-3 (HY- P86370 ) and β-actin (Servicebio, ZB15001-HRP, 1:2000).

Techniques: Biomarker Discovery, Inhibition, Western Blot, Control, Expressing